2021
Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure
Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.Peer-Reviewed Original ResearchConceptsEnd-stage heart failureReduced ejection fractionHealth-related qualityPatient-reported health statusEffect of inotropesHeart failureHealth status domainsEjection fractionHealth statusFunctional statusPositive inotropesStatus domainsAvailable clinical trial dataMorbidity/mortalityPopulation of patientsPatient-centered outcomesHealth status outcomesClinical trial dataFunctional capacity changesQuantity of lifeWeb of ScienceInotrope therapyInotrope useCalcium sensitizerSurvival benefit
2019
The Characteristics of Out-Patient Use of Intravenous Milrinone in the United States
Gottlieb S, Grabowsky T, Allen L, Kandel B, Apte J, Desai N, Ahmad T, Clark S, Psotka M, Lindefeld J, Francis G. The Characteristics of Out-Patient Use of Intravenous Milrinone in the United States. Journal Of Cardiac Failure 2019, 25: s88-s89. DOI: 10.1016/j.cardfail.2019.07.253.Peer-Reviewed Original ResearchMilrinone useAdvanced heart failure treatmentConcomitant medication useUse of milrinoneHeart failure treatmentBeta-adrenergic blockersOut-patient useNature of patientsTotal US populationFentanyl prescriptionsInotrope useIntravenous milrinoneCardiac medicationsLoop diureticsMedication useMean ageAcute eventOutpatient settingFailure treatmentAdrenergic blockersLife careMilrinoneLower prescriptionUS populationNational projections